Vaccinex, Inc. (VCNX:NASDAQ) Annual Reports & Investor Relations Material

Overview

Vaccinex Inc. is a clinical-stage immunotherapy company focused on developing targeted biotherapeutics to treat unmet medical needs, including cancer and neurodegenerative diseases. The company is currently conducting clinical trials on Non-Small Cell Lung Cancer and Huntington’s disease. Vaccinex is utilizing its proprietary drug discovery platform, ActivMAb®, to expand its pipeline and develop high-value antibodies to multi-pass membrane receptors. Based in Rochester, New York, the company is also seeking strategic collaborations to accelerate its drug development efforts.

Frequently Asked Questions

What is Vaccinex, Inc.'s ticker?

Vaccinex, Inc.'s ticker is VCNX

What exchange is Vaccinex, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Vaccinex, Inc.'s headquarters?

They are based in Rochester, New York

How many employees does Vaccinex, Inc. have?

There are 11-50 employees working at Vaccinex, Inc.

What is Vaccinex, Inc.'s website?

It is http://www.vaccinex.com/

What type of sector is Vaccinex, Inc.?

Vaccinex, Inc. is in the Healthcare sector

What type of industry is Vaccinex, Inc.?

Vaccinex, Inc. is in the Biotechnology industry

Who are Vaccinex, Inc.'s peers and competitors?

The following five companies are Vaccinex, Inc.'s industry peers:

- Intra-Cellular Therapies

- Aptorum Group Limited

- Liminal BioSciences

- UroGen Pharma Ltd.

- 4basebio PLC